(Total Views: 804)
Posted On: 08/19/2020 2:21:33 AM
Post# of 155128
As far as I know, there's no evidence to suggest that pursuing the COVID indication contributed to the HIV BLA getting delayed.
If leronlimab can help people suffering from COVID, the choice to 'go for it' was correct, from both an ethical perspective and ultimately, IMO, from a shareholder's perspective.
If leronlimab can help people suffering from COVID, the choice to 'go for it' was correct, from both an ethical perspective and ultimately, IMO, from a shareholder's perspective.

